Recently, the Genetic Nutrition Functional Medicine Association, in collaboration with GBC and Leopard Gene, jointly organized a seminar on "Precision Medicine in Comprehensive Health" that garnered significant attention from the medical and industry sectors. The event aimed to delve into new trends and breakthrough innovations in the field of medical technology. Esteemed speakers with extensive expertise in various domains were invited to share their experiences and insights, shedding light on the current applications of precision medicine in promoting a healthy lifestyle.
Precision medicine is a global trend in medical development, and Taiwan is actively advancing its development. The emphasis is on encouraging medical institutions to collaborate with the biotechnology industry, mutually supporting each other and establishing databases tailored to the Taiwanese population.
The seminar, organized by the Genetic Nutrition Functional Medicine Association and co-hosted by GBC and Leopard Gene, explored several crucial topics:
1) Clinical applications and development trends of the next-generation CTC (Circulating Tumor Cell) detection.
2) Prospective developments and applications of Next-Generation Sequencing (NGS)
3) Medical integration and future prospects in emerging healthcare models
The precision medicine trend in cancer treatment is no longer confined to tracking and treating primary or metastatic cancers. Instead, it encompasses a broader spectrum of precision medicine combined with preventive medicine. During the seminar, GBC provided a detailed and multifaceted introduction to the CellBio™ platform for detecting CTCs. Attendees, including guests and expert scholars, were impressed and praised GBC for its innovative approach.
The GBC CellBio™ technology platform employs patented membrane filtration technology, achieving a recovery rate of over 90%, ensuring no loss of potential circulating tumor cells. The physical collection method preserves the complete morphology of circulating tumor cells, facilitating the subsequent development and application of the platform (such as NGS, WGS, RT-PCR, cell culture, anticancer drug sensitivity testing, etc.). The open fully automated detection system for circulating tumor cells eliminates the need for sample pre-processing, reducing human error and cell loss issues.GBC is also developing high-throughput and low-throughput instruments based on customer needs, aiming to enhance market competitiveness and functionality.
Looking ahead, GBC is committed to contributing further to the development of medical technology and the advancement of precision medicine. The company expresses gratitude to all participants for their support and contributions to this event!
Precision medicine is a global trend in medical development, and Taiwan is actively advancing its development. The emphasis is on encouraging medical institutions to collaborate with the biotechnology industry, mutually supporting each other and establishing databases tailored to the Taiwanese population.
The seminar, organized by the Genetic Nutrition Functional Medicine Association and co-hosted by GBC and Leopard Gene, explored several crucial topics:
1) Clinical applications and development trends of the next-generation CTC (Circulating Tumor Cell) detection.
2) Prospective developments and applications of Next-Generation Sequencing (NGS)
3) Medical integration and future prospects in emerging healthcare models
The precision medicine trend in cancer treatment is no longer confined to tracking and treating primary or metastatic cancers. Instead, it encompasses a broader spectrum of precision medicine combined with preventive medicine. During the seminar, GBC provided a detailed and multifaceted introduction to the CellBio™ platform for detecting CTCs. Attendees, including guests and expert scholars, were impressed and praised GBC for its innovative approach.
The GBC CellBio™ technology platform employs patented membrane filtration technology, achieving a recovery rate of over 90%, ensuring no loss of potential circulating tumor cells. The physical collection method preserves the complete morphology of circulating tumor cells, facilitating the subsequent development and application of the platform (such as NGS, WGS, RT-PCR, cell culture, anticancer drug sensitivity testing, etc.). The open fully automated detection system for circulating tumor cells eliminates the need for sample pre-processing, reducing human error and cell loss issues.GBC is also developing high-throughput and low-throughput instruments based on customer needs, aiming to enhance market competitiveness and functionality.
Looking ahead, GBC is committed to contributing further to the development of medical technology and the advancement of precision medicine. The company expresses gratitude to all participants for their support and contributions to this event!
){kind=link}